<DOC>
	<DOCNO>NCT03033095</DOCNO>
	<brief_summary>The aim trial caracterisation predict algorithm answer response patient etanercept treatment spondyloarthritis disease . This algorithm help target patient patient risk / benefit important etanercept treatment .</brief_summary>
	<brief_title>Prediction Answer Treatment Biotherapies Naive Spondyloarthritis Combinatorial Analysis Serum Biomarkers</brief_title>
	<detailed_description>Spondyloarthritis ( spondyloarthropathy ) inflammatory rheumatic disease cause arthritis . It differ type arthritis involve site ligament tendon attach bone call `` entheses . '' All patient get physical therapy make exercise joint . Exercises promote spinal extension mobility recommend . Non-steroidal anti-inflammatory drug ( NSAIDs ) first line treatment spondylarthritis . NSAIDs effective use continuously request , short long-term use . However , physician aware potential cardiovascular , renal gastro-intestinal secondary effect prescribe NSAIDs . After NSAIDs failure , TNF inhibitor use , like infliximab etanercept . Before start anti-TNF treatment , screen mandatory . Indeed , patient treat anti-TNF must follow regularly . Until , algorithm predict response TNF-inhibitors , especially etanercept treatment . In clinical trial , investigator want caracterise algorithm predict response etanercept cohort patient suffer spondyloarthritis . The development predictive algorithm etanercept treatment set biological data finalize availibility clinical data ( M6 ) patient . A modelling logistic regression use , incorporing set available variable . In clinical trial , investigator want caracterise algorithm predict response TNF-inhibitors cohort patient Spondyloarthritis indicate treatment etanercept .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>patient spondylarthritis validate ASAS New York modify critera , etanercept indicate . Na√Øve biological Drug Modifying Anti Rheumatic Drugs patient 18 70 year old patient monitor 6 month ; patient observe entire treatment ; patiens age procreate effective contraception ( ( abstinence , oral contraceptive , intrauterine device , implant , spermicide surgical sterilization ) study 6 month , 3 week last injection . patient able understand accept term study patient sign informed consent . patient insured social security patient age protect ; patient difficulty understand french language ; patient high function disorder incompatible education program ( dementia Alzheimer 's type , etc ... ) ; patient psycho social instability incompatible regular monitoring ( homeless , addictive behavior , etc . ) ; patient socio professional situation incompatible optimal attendance program Pregnant nursing patient patient receive previously biotherapy treatment . There exclusion criterion take account previous treatment duration . contraindication use anti TNF treatment Surgery schedule study . Persons mention Articles L.11215 L.11218 Public Health Code</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>TNF inhibitor</keyword>
	<keyword>Etanercept</keyword>
	<keyword>Spondyloarthritis</keyword>
	<keyword>Biomarkers analysis</keyword>
	<keyword>Personnalized medicine</keyword>
</DOC>